Mediators produced during inflammation are responsible for hyperalgesia and expression of neurotransmitters and receptors in the nervous system. The production of bradykinin (BK) and the prostaglandins (PGs) may regulate initiation of pain. This study tested the hypothesis that BK and prostaglandin E2 (PGE2) have a positive interaction in evoking neurosecretion of immunoreactive calcitonin gene-related peptide (iCGRP). Bovine dental pulp was prepared and stimulated by the superfusion method with BK alone and in combination with PGE2. Kinin receptor antagonists to bradykinin-evoked release of iCGRP were also tested. Also tested was the hypothesis that dental pulp contains either the B, or B2 or both BK receptors. Results showed that PGE2 enhanced BK-evoked iCGRP release by more than 50%. Western immunoblots revealed detectable B2 receptor protein with no detectable B1 receptor protein. We conclude that BK evokes iCGRP release from bovine dental pulp which is enhanced by a positive interaction with PGE2. Neurosecretion is evoked from isolated terminals of dental pulp fibers via the bradykinin B2 receptor-dependent mechanism.
INTRODUCTION
Inflammation is a common and complex feature of clinical pain resultillg from injury to a tissue. Mediators produced during inflammation are responsible for hyperalgesia, alterations in cell phenotype, and the expression of new molecules (neurotransmitters, enzymes, receptors) in the peripheral and central nervous systems. Among the inflammatory mediators, the productioll of bradykinin (BK) and the prostaglandins (PGs) is thought to be importanit in regulating the initiation of pain and the facilitation of nociceptor signaling that produces hyperalgesia (Holzer, 1988; Dray et al., 1992) . The interactions are complicated, since BK activates a subclass of nociceptive afferenit neuLronis, while also evoking the formation of the PGs, which sensitize those same neurons to BK. This positive interaction between BK and PG has been demonstrated by biochemical, electrophysiologic, and exocytotic-dependent measures (Chahl and Iggo, 1977; Andreeva and Rang, 1993;  Rueff and Dray, 1993; Teixeira et al., 1993; Nicol and Cui, 1994;  Cui and Nicol, 1995; Evans et al., 1996; Stucky et al., 1996) . However, comparatively few studies have evaluated whether an interaction exists between these mediators in regulatilng peripheral neurosecretion from peripheral terminals. The latter point is physiologically significant, since inflammlilatory mediators are released in peripheral tissue and since periplheral neLlrosecretion of neuropeptides such as calcitonin gene-related peptide (CGRP) is implicated in the mediation of neurogenic inflammationi, pulpal necrosis, and wound healing (Holzer, 1991; Byers and Taylor, 1993; Kerezoudis et a!., 1995) . Accordingly, we have tested the hypothesis that BK and PGE, have a positive interaction in evoking neurosecretion from terminals innervating dental pulp. Dental pulp was selected as a model tissue since application of any physiologic stimulus to human dental pulp including thermal, osmotic, chemical, or mechanical-produces only a pain sensation (Anderson and Matthews, 1967; Edwall and Olgart, 1977; Ahlquist et a!., 1984 Ahlquist et a!., , 1985 . Thus, virtually all sensory neurons that innervate pulp appear to be nociceptors.
Recently, two gene products have been identified as the B, and B, bradykinin receptors (Menke et al., 1994; Pesquero et al., 1994; Kanmllerer et al., 1995) . However, it is not known whether dental pulp contains the Bi and/or B2 forms of the receptor. In addition, it is not known which receptor mediates BK-evoked neurosecretion from this tissue. Thus, we also have tested, using both pharmacological antagonists and Western iimmunoblots, the hypothesis that dental pulp contains the B l and B2 receptors.
MATERIALS & METHODS
The protocol for the use of teeth removed from freshly killed cows was reviewed by the appropriate animal use committee at the University of Minnesota, and an exception was granted since the teeth and pulp tissue were obtained firom animals after they were killed.
Superfusion
The superfusion method was followed as previously described (Har-gr-eaves et al., 1992) . Immunoreactive CGRP was selected as the evoked responise in these Figure 1 . Concentration-dependent effect of bradykinin (BK) on evoking iCGRP release from superfused bovine dental pulp. Exposure to BK (1 pM) produced a significant increase in spontaneous release of iCGRP relative to basal levels. BK evoked a 63.0 ± 1 3.2% maximal increase in iCGRP release. Data were analyzed by ANOVA (mean ± SEM) (p < 0.05) (n = 42). experiments since its presence is 10-to 20-fold greater than that of SP in bovine dental pulp; thus the study could be conducted with fewer animals. Bovine dental pulp is a highly innervated peripheral tissue (Uddman et al., 1986) and is easily obtainable. Mandibular bovine pcrnanent incisor teeth from adult animals (2-3 yrs of age) were removed at the slaughterhousc, placed on ice, and brought to the laboratory. The teeth were split with bolt cutters and the pulp tissue removed, sectioned into 2-mm slabs, and chopped (perpendicular to the long axis) into 200-pum slices (Mclwain Tissue Chopper, Gomshall, Surrey, England). The slices were weighed (ca. 325 mg) and placed into 1.5-mL superfusion chambers, which were pumped with Krebs buffer (36°C; pH 7.4) at a rate of 0.33 mL/min. After a recovery period of 77 min for tissue acclimation, fractions were collected every 7 min, starting with fracton #12, for the duration of the experiment. The presence and distribution of immunoreactive CGRP nerve fibers follow the work of Uddman et al. (1986) . Using immunohistochemical methods, they found similar distribution and numbers of fibers in cows and humans.
Radioimmunoassay
Superfusate levels of immunoreactive CGRP (iCGRP) were measured by means of a previously validated radioimmunoassay (Hargreaves et a!., 1992) . Superfusate samples (2.1 mL) were preincubated for 48 hrs at 4°C with CGRP antisera (courtesy of Dr. Michael ladarola, NIDCR, NIH, Bethesda, MD, USA). The radiolabeled tracer 8 83 (approximately 20, 000 cpm) and 50 ItL of goat anti-rabbit antisera coupled to ferric beads (PerSeptive Diagnostics, Cambridge, MA, USA) were added and allowed to incubatc for an additional 48 hrs at 4'C. Bound and free tracer were separatcd by immunomagnetic separation. The minimum detection of the assay is 3 fmol/tube with a 50% displacement of 20 fmol/tube. All drugs were tested for interference in the RIA, and there was no cross-reactivity at the concentrations used in thesc studies. Effect of prostaglandin E2 bradykinin-evoked release of iCGRP from bovine dental pulp. Bovine dental pulp was superfused with indomethacin used to block endogenous PGE2. PGE release 110 pM), prior to treatment with BK (1 pM) alone and in comtinotion with PGE significantly increased release of iCGRP-from 33% to 52% over basal levels (mean ± SEM) (p < 0.05) (n = 48).
To detennine the effect of BK alone and in combiniationi with prostaglandin E, (PGE,) on superftisatc levels of iCGRP, we first characterized the concentration-response curve for bradykinin-induced iCGRP release. Bradykinin (1-10,000 nM) or vehicle (Krebs) was applied at fraction #18. At the completion of the experiment, we applied capsaicin (30 pM) to all chambers (fractions #22 and #23) to demonstrate continued tissue viability by measuring turtlherrelease of iCGRP after stimulation with various drug treatmncits.
Next, we evaluated whether administration of PGE, alters BK-evoked relcase of iCGRP. To remove endogenous sources of prostanoids, we pre-treated all chambers with indomethaciin (5 pM). Chambers were then administered either PGE, (10 pM) or vehicle and then stimulated with bradykinin (I ptM). At the completion of the experiment, all chambers were stillulated with capsaicin (30 ,uM) for verification of continued tissuc viability.
Immunoblotting
We used two general approaches to evaluate whether the B, or B, receptor mediates BK-evoked release of iCGRP fiom dcntal pulp. The superfusion experiment evaluated whether pre-treatment with a bradykinin Bi receptor antagonist (DesArg"' [HOE 140] ) or a bradykinin receptor B, antagonist (HOE-140) reduced BK-evoked release of iCGRP from dental pulp (Costello and Hargreaves, 1989) . The immunoblot experiment evaluated whether the Bl or B, receptor could be detected in dental pulp. Fresh bovine dcntal pulp was weighed and homogenized in lysis butfer, then centrifuged. The supernatant was collected and prepared lor loading onto 4%/0700 stacking polyacrylamidc gel in sample loading bulffer (4X 2% SDS, 0.5% 0-mercaptoethanol, 0.0625 M Tris, 7.5% glycerol, and 0.01% bromophenol bluc). Proteins were separated by SDS-PAGE, transferred to nitrocellulose, and incubated with the polyclonal anti-B, antisera ( Figure 3 . Effect of pre-treatment with BK receptor antagonists on bradykinin-evoked release of iCGRP from dental pulp. Bovine dental pulp exposed to BK (1 pM) produced significant increases in iCGRP release relative to basal levels (mean ± SEM) (p < 0.01). Pre-treatment with the B receptor antagonist (HOE 140) significantly inhibited BKevoked reSease of iCGRP (p < 0.05), while pre-treatment with the B1 receptor antagonist (des argl°[HOE 140]) had only a slight effect (mean ± SEM) (p < 0.05) (n = 48).
Hercules, CA, USA). Species of antiserum used was mouse. The antibody tested as reactive in human, dog, rat, and chick B2 bradykinin receptors. The positive control used was rat pituitary lysatc. Negative controls omitted the primary antibody and the secondary antibody. Following incubation with secondary antibodies (goat anti-mouse antibody), the blots were washed, incubated with a strep-avidin complex for I hr, washed 4X for 5 min each, developed with AB developer solution for 30 min (BioRad, Hercules, CA, USA), dried, and examined.
The drugs were purchased from the following laboratories: prostaglandin E2, Des Argl°[HOE 140] (B1 antagonist) and bradykinin (Peninsula Laboratories, Belmont, CA, USA); indomethacin and capsaicin (Sigma Chemical Co., St. Louis, MO, USA); and HOE 140 (B2 antagonist) (RBI, Natick, MA, USA).
Statistics
Data are presented as means = SEM. Statistical significance was determined by two-way ANOVA with repeated measures, followed by Duncan's multiple-range post hoc analysis with significance at p < 0.05.
RESULTS
The concentration response curve for BK alteration of iCGRP release from dental pulp is illustrated in Fig. 1 . BK evokes iCGRP release with an ECQ0 value of -60 nM. Maximal release of iCGRP was observed at a BK concentration of I 1iM. Higher concentrations of BK tended to reduce iCGRP release levels, possibly through a receptor desensitization mechanism.
The effect of PGE2 pre-treatment on BK-evoked iCGRP release is presented in Fig. 2 . Administration of PGE2 by itself had no effect on iCGRP release as compared with vehicle treatment (data not shown). Administration of BK alone replicates the findings from Fig. 1 , with a l-pM concentration evoking a 45% increase in iCGRP release (p < 0.05). In addition, the combination of PGE2 enhanced BK-evoked iCGRP release by more than 50% (p < 0.05). J Dent Res 79(8) 2000 Figure 4 . Western blot demonstrating B2 bradykinin receptor in bovine dental pulp. Proteins were separated by SDS-PAGE, transferred to nitrocellulose, and probed with anti-B antiserum. Detectable protein was found as a single 44-kDa band. No corresponding level of detectable B1 receptor protein was found.
We then conducted two experiments to evaluate whetlher the BK-evoked release of iCGRP is mediated by the B1 or B, bradykinin receptor. The effect of pre-treatment with a B antagonist (Des Argl' -[HOE 140]) or a B, antagonist (HOE-140) on BKevoked iCGRP release is illustrated in Fig. 3 . Exposure to BK (I ,tM) produced a significant increase in peptide release relative to control values. Pre-treatment with the B2 receptor antagonist, but not the B1 antagonist, significantly inhibited that release.
The Western immunoblots were then evaluated for the presence of immunoreactive B and B, receptor proteins in dental pulp (Fig. 4) . The blots reveal detectable B, protein migrating as a single 44-kDa band. In contrast, there was no corresponding level of detectable B, receptor in dental pulp detected in the 41-kDa range (the predicted size of the B1 receptor).
DISCUSSION
Although BK is known to stimulate pain in humans, comparatively few studies have evaluated BK regulation of neurosecretion in dental pulp. The present study evaluated two hypotheses: first, that BK evokes iCGRP release from dental pulp with a positive interaction with the inflammatory mediator PGE,; and second, that BK activates a receptor-dependent mechanism via interaction with either the B, or B2 bradykinin receptor classes.
Our results support both hypotheses. The initial studies demonstrate that BK potently evokes neurosecretion of iCGRP from dental pulp, with detectable release occurring at BK concentrations near 10 nM and maximal effects occurring at 1 tM. Combined pre-and co-treatments with PGE2 enhanced BK-evoked iCGRP release by more than 50%. It is important to note that administration of PGE2 by itself failed to alter iCGRP release. This is similar to the results of prior electrophysiologic studies in which PGE2 sensitized neurons to the subsequent administration of BK. This effect is thought to be due to activation ofprostanoid receptors coupled to Gs-mediated signal transduction mechanisms (Dray et al., 1992) .
Several findings support the general conclusion that this BK effect in dental pulp is receptor-mediated. Importantly, the BKevoked iCGRP release is concentration-dependent, has a saturable maximal effect, and is blocked by a competitive antagonist. Moreover, the results support the hypothesis that this effect is mediated by activation of the B2 receptor, since it is blocked by a B2 antagonist (HOE-140), and since the B2 receptor protein is detectable in this same tissue. Data do not support a role for the B1 receptor. Under these experimental conditions, a Bi receptor antagonist failed to alter BK-evoked iCGRP release, and the Westem immunoblots failed to detect B1 protein. Analysis of these data indicates that BK does not mediate neurosecretion in normal pulp via a B1 receptor-dependent mechanism. Thus, we conclude that BK evokes neurosecretion from isolated terminals of dental pulp fibers via a B2 receptor-dependent mechanism.
Since BK is released during inflammation, the present results are consistent with the hypothesis that BK contributes to the initiation of neurogenic inflammation in dental pulp via enhanced secretion of neuropeptides such as CGRP. Since an intact and functional peripheral distribution of peptidergic fibers is important in wound healing (Kerezoudis et al., 1995) and altering rates of pulpal necrosis (Byers and Taylor, 1993) , it is also possible that pulpal levels of BK represent a physiologically significant factor in regulating pulpal responses to injury or inflammation. This study has provided pharmacological and immunological (Westem blot) evidence of the B2 receptor in dental pulp, but fiuther studies are required to characterize their distribution. It is possible that regulation of BK levels in pulpal inflammation will have clinical significance in altering tissue inflammation, healing, and pain.
